Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
Brun MK, Bjørlykke KH, Viken MK, Stenvik GE, Klaasen RA, Gehin JE, Warren DJ, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Haavardsholm EA, Jahnsen J, Goll GL, Lie BA, Bolstad N, Jørgensen KK, Syversen SW. Brun MK, et al. Among authors: jahnsen j. J Intern Med. 2023 May;293(5):648-655. doi: 10.1111/joim.13616. Epub 2023 Feb 26. J Intern Med. 2023. PMID: 36843323
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
Syversen SW, Jyssum I, Tveter AT, Sexton J, Christensen IE, Tran TT, Bjørlykke KH, Mjaaland S, Warren DJ, Kvien TK, Chopra A, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Grødeland G, Vaage JT, Provan SA, Jørgensen KK, Goll GL. Syversen SW, et al. Among authors: jahnsen j. RMD Open. 2022 Nov;8(2):e002417. doi: 10.1136/rmdopen-2022-002417. RMD Open. 2022. PMID: 36328399 Free PMC article.
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study.
Bjørlykke KH, Ørbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, Christensen IE, Kro GB, Kvien TK, Jahnsen J, Munthe LA, Chopra A, Warren DJ, Mjaaland S, Haavardsholm EA, Grødeland G, Provan SA, Vaage JT, Syversen SW, Goll GL, Jørgensen KK. Bjørlykke KH, et al. Among authors: jahnsen j. Lancet Rheumatol. 2023 Jan;5(1):e36-e46. doi: 10.1016/S2665-9913(22)00330-7. Epub 2022 Nov 16. Lancet Rheumatol. 2023. PMID: 36415604 Free PMC article.
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW. Brun MK, et al. Among authors: jahnsen j. Lancet Rheumatol. 2024 Apr;6(4):e226-e236. doi: 10.1016/S2665-9913(23)00341-7. Epub 2024 Feb 22. Lancet Rheumatol. 2024. PMID: 38402891 Clinical Trial.
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.
Ørbo HS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Christensen IE, Mjaaland S, Kvien TK, Grødeland G, Kro GB, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Goll GL, Jørgensen KK, Syversen SW. Ørbo HS, et al. Among authors: jahnsen j. RMD Open. 2024 Apr 9;10(2):e003545. doi: 10.1136/rmdopen-2023-003545. RMD Open. 2024. PMID: 38599653 Free PMC article.
Discontinuation of Infliximab Therapy in Patients with Crohn's Disease.
Buhl S, Steenholdt C, Brynskov J, Christensen KR, Dorn-Rasmussen M, Thomsen OØ, Bendtzen K, Klausen TW, Dahlerup JF, Thorsgaard N, Jahnsen J, Molazahi A, Pedersen N, Kjeldsen J, Almer S, Dahl EE, Vind I, Cannon AG, Marsal J, Sipponen T, Agnholt JS, Kievit HAL, Aure SL, Martinsen L, Meisner S, Hansen JM, Ainsworth MA. Buhl S, et al. Among authors: jahnsen j. NEJM Evid. 2022 Aug;1(8):EVIDoa2200061. doi: 10.1056/EVIDoa2200061. Epub 2022 Jun 14. NEJM Evid. 2022. PMID: 38319804
Human small intestine contains 2 functionally distinct regulatory T-cell subsets.
Chauhan SK, Bartolomé Casado R, Landsverk OJB, Johannessen H, Phung D, Nilsen HR, Sætre F, Jahnsen J, Horneland R, Yaqub S, Aandahl EM, Lundin KEA, Bækkevold ES, Jahnsen FL. Chauhan SK, et al. Among authors: jahnsen j. J Allergy Clin Immunol. 2023 Jul;152(1):278-289.e6. doi: 10.1016/j.jaci.2023.02.030. Epub 2023 Mar 8. J Allergy Clin Immunol. 2023. PMID: 36893861 Free article.
Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis.
Das S, Stamnaes J, Kemppainen E, Hervonen K, Lundin KEA, Parmar N, Jahnsen FL, Jahnsen J, Lindfors K, Salmi T, Iversen R, Sollid LM. Das S, et al. Among authors: jahnsen j. Adv Sci (Weinh). 2023 Sep;10(25):e2300401. doi: 10.1002/advs.202300401. Epub 2023 Jul 9. Adv Sci (Weinh). 2023. PMID: 37424036 Free PMC article.
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.
Schuppan D, Mäki M, Lundin KEA, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde Ø, Lähdeaho ML, Fusco S, Schumann M, Török HP, Kupcinskas J, Zopf Y, Lohse AW, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R; CEC-3 Trial Group. Schuppan D, et al. Among authors: jahnsen j. N Engl J Med. 2021 Jul 1;385(1):35-45. doi: 10.1056/NEJMoa2032441. N Engl J Med. 2021. PMID: 34192430 Free article. Clinical Trial.
177 results